Rivaroxaban and aspirin are drugs that reduce blood clots in blood vessels and are currently being given to some patients with CAD and PAD. The combination of rivaroxaban with aspirin is being developed as a more effective treatment. If licensed, this combination will offer a new option for the prevention of major cardiovascular events.
Rivaroxaban (Xarelto) in Combination with Aspirin for Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
Interventions:
Rivaroxaban (Xarelto; BAY 59-7939)
Indications:
Cardiovascular disease (CVD)
Therapeutic Areas:
Cardiovascular System
Year:
2017